Collection of Transplant Stem Cells for Plasma Cell Myeloma
Mobilization and Collection of Autologous Stem Cell for Transplantation (ASCT) for Plasma Cell Myeloma (PCM)
Sponsor: National Cancer Institute (NCI)
A PHASE2 clinical study on Multiple Myeloma and Plasma Cell Myeloma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 12 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
-
May 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .